Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2010

View Archived Issues

ARQ-621 well tolerated to date in phase I study

Emory University claims novel HSP 90 inhibitors

Argenta Discovery claims novel CRTH2 receptor antagonists

Novel activators of hyaluronan transport disclosed by German scientists

Amira Pharmaceuticals describes novel DP2 receptor antagonists

Novel p38alpha MAPK inhibitors identified by Amgen

Dual VEGFR-2/HGFR inhibitor ASP-08126 shows promising preclinical potential

Multiplex PI3K inhibitors suppress Ras-mutated tumors in vitro and in vivo

Rivastigmine patch improves hepatic encephalopathy in clinical trial

New biomarkers of end-stage renal disease identified

Scancell obtains approval to conduct trial for SCIB-1 melanoma vaccine

Ariad and MSD restructure collaboration for ridaforolimus in oncology

Bayer Schering and EndoCeutics form global agreement for intravaginal DHEA

FDA clearance for Aradigm's inhaled liposomal ciprofloxacin trial in CF pediatric patients

BELLUS discontinues NC-503 development for diabetes following proof-of-concept study

Ralfinamide does not meet primary endpoint in topline results from Newron's SERENA trial

Novo Nordisk to begin phase III cardiovascular outcomes trial for Victoza in fall 2010

Keryx initiates phase III registration program for Zerenex

Boehringer Ingelheim and Micromet collaborate for multiple myeloma antibody

Eisai seeks approval in Japan for twice-daily dosing of Pariet for reflux esophagitis

Novocell changes name to ViaCyte

Synergistic tolerogenic effects seen with RGI-2001 and anti-thymocyte globulin in vivo

FDA review sets new PDUFA action date for Bydureon

Acceleron initiates phase II ACE-031 trial in Duchenne muscular dystrophy

CNTO-2476 well tolerated in first-in-human study in patients with retinitis pigmentosa

Sinovac submits application to begin clinical trials for mumps vaccine in China

Bayer receives FDA approval for Natazia for prevention of pregnancy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...